669 results
Primary: Safety and tolerability of fingolimod 0,5 mg.Secundairy: Efficacy and quality of life.
The primary objective is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of RA in subjects with active RA who are refractory to an anti-TNF Alpha agent. The secondary objectives are to assess the following…
Primary ObjectiveThe primary objective of this study is to compare prospectively in patients treated with TCZ or etanercept (ETA), the time to first occurrence of any component of a composite of major adverse cardiovascular events (MACE) consisting…
To characterize the profile of low BMD in >= 50 years old male HIV-1 infected subjects andpost-menopausal female HIV-1 infected subjects taking TDF-based regimens relative tothose taking non-TDF-based regimens for HIV infection.
Objectives: • To provide continuing treatment to subjects with SLE who complete HGS1006-C1056 or HGS1006-C1057.• To evaluate the long-term safety and tolerability of belimumab in subjects with SLE.
Primary objective:To evaluate the efficacy of a RPV based HAART in patients that switch from NVP with FTC, TDF or lamivudine (3TC), TDF or 3TC, zidovudine (ZDV) to RPV/FTC/TDF.Secondary objectives:To measure the impact (strength and duration) of NVP…
to combine and validate diagnostic and prognostic tests for patients with recently diagnosed rheumatoid arthritis to predict joint damage and response to (DMARD) therapy.
The purpose of this study in patients with primary progressive multiple sclerosis (PPMS) is to evaluatewhether FTY720 is effective in delaying MS disability progression in the absence of relapsescompared to placebo. Furthermore, safety and…
The main objective of the study is to investigate whether the strong clinical effects of natalizumab in RRMS can be explained by enhanced functional adaptation mechanisms of the brain and whether enhanced functional reorganisation is sustained over…
To investigate the effect on symptomatology of interference with IL-1 in CFS patients.
The objective of this study is to explore the efficacy and safety of gevokizumab in patients with Schnitzler syndrome.
1. Clinically relevant reduction of symptom severity by use of Citrus/Cydonia comp. subcutaneous injections 2. To examine the use of rescue medication in the three groups, 3.safety of treatment
The focus of this pilot study is to investigate the results of a sialendoscopy (with or without rinsing with hydrocortisone 100mg) on the unstimulated whole mouth (UWS) and stimulated parotid (SP) (ml/min) flow of saliva, oral dryness, reported…
The overall purpose of the trial is to assess clinical efficacy and safety of three different doses of BI 655066 administered by multiple subcutaneous injections in adult patients with defined ankylosing spondylitis. We will also explore its…
The objective of this study is to evaluate the efficacy and safety of continuing versus withdrawing therapy with adalimumab 40 mg given every other week (eow) SC in maintaining remission in subjects with nr-axSpA.
The aim of the study is to examine in 144 patients with primary Sjögren*s syndrome, non-Sjögren sicca syndrome, rheumatoid arthritis and systemic lupus erythematosus, whether a intervention consisting of cognitive-behavioural therapy combined with…
Part 1: To assess the safety, tolerability and pharmacokinetic-dynamic response, of single escalating doses of EA-230 in healthy subjects.Part 2: To assess the dose-and plasma concentration-response relation of single escalating doses EA-230 on…
The primary objective of this study is to assess whether there is transfer of CZP across theplacenta to infants from mothers by evaluating the concentration of CZP in the plasma of infants.The secondary and exploratory objectives are to assess the…
To determine the proportion of patients with JIA maintaining minimal disease activity (MDA) after dose interval prolongation of etanercept. Secondary objectives: To study the cost-effectiveness of tapering down etanercept treatment, to investigate…
Primary objective: to assess the inhibition of allergic responses of a single dose of subcutaneously (SC) administered REGN1908-1909 as measured by total nasal symptom score (TNSS), visual analog scale (VAS) nasal symptoms score, and peak nasal…